{{Rsnum
|rsid=666553
|Gene=PGR
|Chromosome=11
|position=101067937
|Orientation=plus
|GMAF=0.1786
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PGR
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 73.8 | 26.2 | 0.0
| HCB | 55.6 | 40.0 | 4.4
| JPT | 63.6 | 27.3 | 9.1
| YRI | 63.5 | 31.7 | 4.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 55.6 | 40.0 | 4.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[http://www.medpagetoday.com/MeetingCoverage/SMFM/12729 news]  The effectiveness of [[17 alpha-hydroxyprogesterone caproate]] for prevention of recurrent preterm birth is influenced by SNPs.

Black women
*[[rs471767]] homozygous for the major allele treatment significantly reduced the rate of preterm birth.
*[[rs578029]] who had a least one copy of the major allele, treatment significantly reduced in preterm birth

non-black women
*a least one copy of the minor allele of [[rs503362]] had a significant reduction with treatment
*with at least one copy of the minor allele of [[rs666553]] had a significant reduction in very preterm birth

{{PMID Auto
|PMID=21600550
|Title=Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}